PL2719384T3 - Nowe 1-naftylo-3-azabicyklo[3.1.0]heksany: wytwarzanie i zastosowanie do leczenia zaburzeń neuropsychiatrycznych - Google Patents

Nowe 1-naftylo-3-azabicyklo[3.1.0]heksany: wytwarzanie i zastosowanie do leczenia zaburzeń neuropsychiatrycznych

Info

Publication number: PL2719384T3
Authority: PL; Poland
Prior art keywords: azabicyclo; hexanes; naphthyl; novel; preparation
Prior art date: 2005-07-27

Application number

PL13189441T

Other languages

English (en)

Inventor

Phil Skolnick

Anthony Basile

Zhengming Chen

Joseph W. Epstein

Original Assignee

Otsuka America Pharmaceutical, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-27

Filing date

2006-07-25

Publication date

2019-02-28

2006-07-25 Application filed by Otsuka America Pharmaceutical, Inc. filed Critical Otsuka America Pharmaceutical, Inc.

2019-02-28 Publication of PL2719384T3 publication Critical patent/PL2719384T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

PL13189441T 2005-07-27 2006-07-25 Nowe 1-naftylo-3-azabicyklo[3.1.0]heksany: wytwarzanie i zastosowanie do leczenia zaburzeń neuropsychiatrycznych PL2719384T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US70336405P	2005-07-27	2005-07-27
EP06788541A EP1915146A4 (en)	2005-07-27	2006-07-25	NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
EP13189441.2A EP2719384B1 (en)	2005-07-27	2006-07-25	Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
US11/493,431 US20070082940A1 (en)	2005-07-27	2006-07-25	Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
PCT/US2006/029006 WO2007016155A2 (en)	2005-07-27	2006-07-25	Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders

Publications (1)

Publication Number	Publication Date
PL2719384T3 true PL2719384T3 (pl)	2019-02-28

Family

ID=37709141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13189441T PL2719384T3 (pl)	2005-07-27	2006-07-25	Nowe 1-naftylo-3-azabicyklo[3.1.0]heksany: wytwarzanie i zastosowanie do leczenia zaburzeń neuropsychiatrycznych

Country Status (16)

Country	Link
US (9)	US20070082940A1 (pl)
EP (2)	EP2719384B1 (pl)
JP (3)	JP5184354B2 (pl)
KR (3)	KR20170005888A (pl)
CN (2)	CN104059013B8 (pl)
AU (1)	AU2006275870B2 (pl)
BR (1)	BRPI0613943B1 (pl)
CA (1)	CA2659215C (pl)
CY (1)	CY1122238T1 (pl)
IL (2)	IL189008A (pl)
NO (1)	NO343037B1 (pl)
NZ (1)	NZ592836A (pl)
PL (1)	PL2719384T3 (pl)
RU (1)	RU2008107336A (pl)
WO (1)	WO2007016155A2 (pl)
ZA (1)	ZA200801825B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
RU2008107336A (ru)	2005-07-27	2009-09-10	Дов Фармасьютикал, Инк. (Us)	Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
US20100204486A1 (en) *	2006-04-28	2010-08-12	Merck & Co., Inc.	Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes
US20080045725A1 (en) *	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0716633D0 (en) *	2007-08-24	2007-10-03	Glaxo Group Ltd	Compounds
GB0716632D0 (en) *	2007-08-24	2007-10-03	Glaxo Group Ltd	Compounds
GB0804326D0 (en) *	2008-03-07	2008-04-16	Glaxo Group Ltd	Novel compounds
CA2746055C (en) *	2008-12-16	2016-12-13	Sunovion Pharmaceuticals Inc.	Triple reuptake inhibitors and methods of their use
CA2765692A1 (en)	2009-06-26	2010-12-29	Panacea Biotec Ltd.	Novel azabicyclohexanes
WO2012033956A1 (en)	2010-09-08	2012-03-15	Mithridion, Inc.	Cognition enhancing compounds and compositions, methods of making, and methods of treating
WO2012042539A2 (en)	2010-09-28	2012-04-05	Panacea Biotec Ltd	Novel bicyclic compounds
HUE048715T2 (hu) *	2011-07-30	2020-09-28	Otsuka America Pharmaceutical Inc	(1R,5S)-(+)-l-(naftalen-2-il)-3-azabiciklo[3.1.0]hexán alkalmazása monoamin neurotranszmitterek által befolyásolt állapotok kezelésében
US20140206740A1 (en) *	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
JP6284140B2 (ja) *	2013-06-17	2018-02-28	株式会社タムラ製作所	Ｇａ２Ｏ３系半導体素子
KR20160101012A (ko)	2013-12-09	2016-08-24	뉴로반스, 인크.	신규 조성물
CN107921021A (zh) *	2015-06-17	2018-04-17	大塚制药美国公司	结晶化合物
WO2018119291A1 (en) *	2016-12-21	2018-06-28	Otsuka America Pharmaceutical, Inc.	Synthetic methods
US20210078940A1 (en)	2018-04-26	2021-03-18	Api Corporation	Method for manufacturing aromatic nitrile compound
US20220112207A1 (en) *	2019-01-09	2022-04-14	Eisai R&D Management Co., Ltd.	Method for synthesis of diazabicyclo[6.2.0]decane related compounds
EP4046687A4 (en)	2019-10-16	2023-11-15	Otsuka Pharmaceutical Co., Ltd.	METHOD FOR PRODUCING CENTANAFADINE
WO2021085468A1 (ja)	2019-10-29	2021-05-06	株式会社エーピーアイコーポレーション	高純度２－ナフチルアセトニトリル及びその製造方法
CA3205786A1 (en)	2021-02-23	2022-09-01	Otsuka Pharmaceutical Co., Ltd.	Centanafadine pharmaceutical formulations, and methods of making and using same
WO2022256215A1 (en)	2021-05-31	2022-12-08	Teva Pharmaceuticals International Gmbh	Solid state form of centanafadine hcl and process for preparation thereof
JPWO2022265020A1 (pl) *	2021-06-15	2022-12-22
WO2024048782A1 (en)	2022-09-02	2024-03-07	Otsuka Pharmaceutical Co., Ltd.	1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES413944A1 (es)	1972-04-20	1976-06-01	Merz & Co	Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
CS175641B1 (en) *	1973-06-14	1977-05-31	Boris D Babickij	Making method of 2-alkyl-1,3-butadiene's 1,4-transpolymers and/or 2-alkyl-1,3-butadiene's stereoregular 1,4 trans-copolymers with 1,3-butadiene
JPS535994B2 (pl) *	1974-09-26	1978-03-03
US4196120A (en) *	1975-07-31	1980-04-01	American Cyanamid Company	Azabicyclohexanes, method of use and preparation of the same
US4131611A (en) *	1975-07-31	1978-12-26	American Cyanamid Company	Azabicyclohexanes
US4231935A (en) *	1975-07-31	1980-11-04	American Cyanamid Company	1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4088652A (en) *	1975-07-31	1978-05-09	American Cyanamid Company	Acylazabicyclohexanes
GB1532682A (en) *	1976-04-27	1978-11-22	Bristol Myers Co	Process for the preparation of cephadroxil
US4118417A (en) *	1977-06-23	1978-10-03	American Cyanamid Company	Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
US4118393A (en) *	1977-06-23	1978-10-03	American Cyanamid Company	Phenyl azabicyclohexanones
GR72713B (pl)	1976-09-15	1983-12-01	American Cyanamid Co
IL65843A (en)	1977-08-11	1986-12-31	American Cyanamid Co	Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
PL120095B2 (en)	1977-10-04	1982-02-27	Univ Lodzki	Process for preparing novel derivatives of 1,3,3a,6,7,7a-hexahydrodibenzo-/4,5:8,9/-3a,6-ethenisoindolesagidrodibenzo 4,5:8,9-3a,6-ehtenoizoinidola
CH644580A5 (de) *	1980-01-29	1984-08-15	Hoffmann La Roche	Cyclohexen-derivate.
IL63968A (en) *	1980-10-01	1985-10-31	Glaxo Group Ltd	Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4435419A (en) *	1981-07-01	1984-03-06	American Cyanamid Company	Method of treating depression using azabicyclohexanes
US4431661A (en)	1981-08-20	1984-02-14	American Cyanamid Company	5-Aryl-3-azabicyclo[3.2.0]heptan-6-one acetals, and analgesic use therefor
JPS58150526A (ja) *	1982-03-04	1983-09-07	Ube Ind Ltd	光学活性プロパルギルアルコ−ル類およびその製法
EP0100426A1 (en)	1982-07-28	1984-02-15	American Cyanamid Company	3a-(substituted-phenyl)-hexaloctahydro-4,7-alkanoisoindoles
DE3324263A1 (de) *	1983-07-06	1985-01-17	Hoechst Ag, 6230 Frankfurt	Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
US5316759A (en) *	1986-03-17	1994-05-31	Robert J. Schaap	Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) *	1987-07-11	1993-03-30	Sandoz Ltd.	Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) *	1987-07-11	1997-11-27	Sandoz Ag	Neue Verwendung von 5HT¶3¶-Antagonisten
US5075341A (en) *	1989-12-01	1991-12-24	The Mclean Hospital Corporation	Treatment for ***e abuse
US5130430A (en) *	1990-10-31	1992-07-14	Neurogen Corporation	2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US5204366A (en)	1991-06-10	1993-04-20	American Cyanamid Company	2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US6204284B1 (en) *	1991-12-20	2001-03-20	American Cyanamid Company	Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5232934A (en) *	1992-07-17	1993-08-03	Warner-Lambert Co.	Method for the treatment of psychomotor stimulant addiction
US5321012A (en) *	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5556837A (en) *	1994-08-01	1996-09-17	Regeneron Pharmaceuticals Inc.	Methods for treating addictive disorders
US5488056A (en) *	1994-10-31	1996-01-30	Eli Lilly And Company	Method for treating anxiety
US5762925A (en) *	1994-11-03	1998-06-09	Sagen; Jacqueline	Preventing opiate tolerance by cellular implantation
SI1148049T1 (en) *	1995-07-17	2005-02-28	Warner-Lambert Company	Crystalline R-(R,R)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AUPN605795A0 (en) *	1995-10-19	1995-11-09	F.H. Faulding & Co. Limited	Analgesic pharmaceutical composition
ZA969485B (en) *	1995-11-16	1998-05-12	Lilly Co Eli	Excitatory amino acid receptor antagonists.
TW513409B (en) *	1996-06-07	2002-12-11	Eisai Co Ltd	Polymorphs of donepezil hydrochloride
US5905154A (en)	1996-06-10	1999-05-18	American Cyanamid Company	Process for the preparation of 5-(alkoxymethyl)-2,3-pyridinedicarboximide compounds
ZA983930B (en) *	1997-05-14	1999-11-08	Lilly Co Eli	Excitatory amino acid receptor modulators.
US5911992A (en) *	1997-06-12	1999-06-15	A. Glenn Braswell	Method for controlling weight with hypericum perforatum and garcinia cambogia
US6121261A (en) *	1997-11-19	2000-09-19	Merck & Co., Inc.	Method for treating attention deficit disorder
US6245911B1 (en) *	1997-12-05	2001-06-12	Eisai Co., Ltd.	Donepezil polycrystals and process for producing the same
US6245357B1 (en) *	1998-03-06	2001-06-12	Alza Corporation	Extended release dosage form
US6132724A (en)	1998-04-29	2000-10-17	City Of Hope National Medical Center	Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6109269A (en) *	1999-04-30	2000-08-29	Medtronic, Inc.	Method of treating addiction by brain infusion
US6372919B1 (en) *	2001-01-11	2002-04-16	Dov Pharmaceutical, Inc.	(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
EP1453501B1 (en)	2001-12-04	2008-08-13	Schering Corporation	N- aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
CA2475763A1 (en)	2002-02-12	2003-08-21	Cypress Bioscience, Inc.	Methods of treating attention deficit/hyperactivity disorder (adhd)
US20040127541A1 (en) *	2002-07-31	2004-07-01	Janet Codd	Bicifadine formulation
KR20050075382A (ko) *	2002-11-08	2005-07-20	도브 파마슈티칼 인코포레이티드	바이시파딘 하이드로클로라이드의 다형체
FR2859208B1 (fr)	2003-09-02	2006-01-21	Servier Lab	Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT2070922E (pt) *	2004-02-23	2011-11-24	Glaxo Group Ltd	Derivados de azabiciclo(3.1.0)hexano úteis como moduladores dos receptores d3 da dopamina
MX2007001827A (es)	2004-08-18	2007-04-23	Dov Pharmaceutical Inc	Nuevas sustancias polimorfas de azabiciclohexano.
US20060223875A1 (en) *	2005-03-08	2006-10-05	Phil Skolnick	Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
JP2009502798A (ja) *	2005-07-21	2009-01-29	ワイス	神経系障害および状態の処置方法
US20070082939A1 (en)	2005-07-26	2007-04-12	Lippa Arnold S	Methods and compositions for the treatment of neuropathies and related disorders
RU2008107336A (ru)	2005-07-27	2009-09-10	Дов Фармасьютикал, Инк. (Us)	Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
ATE487715T1 (de) *	2005-08-22	2010-11-15	Glaxo Group Ltd	Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
US20090203750A1 (en)	2005-08-24	2009-08-13	Alan Kozikowski	5-HT2C Receptor Agonists as Anorectic Agents
US20100204486A1 (en)	2006-04-28	2010-08-12	Merck & Co., Inc.	Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes
US20080058535A1 (en)	2006-07-25	2008-03-06	Zhengming Chen	Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US20080269348A1 (en) *	2006-11-07	2008-10-30	Phil Skolnick	Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) *	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
KR100837555B1 (ko) *	2006-11-24	2008-06-12	동부일렉트로닉스 주식회사	반도체 소자 및 그 제조 방법
WO2008153937A2 (en)	2007-06-06	2008-12-18	Dov Pharmaceutical, Inc.	Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
HUE048715T2 (hu)	2011-07-30	2020-09-28	Otsuka America Pharmaceutical Inc	(1R,5S)-(+)-l-(naftalen-2-il)-3-azabiciklo[3.1.0]hexán alkalmazása monoamin neurotranszmitterek által befolyásolt állapotok kezelésében
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en)	2011-09-07	2014-08-14	Anthony McKinney	Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
CA2887893C (en)	2012-10-09	2021-07-06	Douglas SEARS	Therapeutic treatment for attention deficit disorder
KR20160101012A (ko)	2013-12-09	2016-08-24	뉴로반스, 인크.	신규 조성물
CN107921021A (zh)	2015-06-17	2018-04-17	大塚制药美国公司	结晶化合物

2006
- 2006-07-25 RU RU2008107336/04A patent/RU2008107336A/ru not_active Application Discontinuation
- 2006-07-25 CN CN201410309301.2A patent/CN104059013B8/zh active Active
- 2006-07-25 AU AU2006275870A patent/AU2006275870B2/en active Active
- 2006-07-25 KR KR1020177000085A patent/KR20170005888A/ko not_active Application Discontinuation
- 2006-07-25 BR BRPI0613943-4A patent/BRPI0613943B1/pt active IP Right Grant
- 2006-07-25 PL PL13189441T patent/PL2719384T3/pl unknown
- 2006-07-25 EP EP13189441.2A patent/EP2719384B1/en active Active
- 2006-07-25 KR KR1020147018408A patent/KR101733180B1/ko active IP Right Grant
- 2006-07-25 NZ NZ592836A patent/NZ592836A/xx unknown
- 2006-07-25 EP EP06788541A patent/EP1915146A4/en not_active Withdrawn
- 2006-07-25 CA CA2659215A patent/CA2659215C/en active Active
- 2006-07-25 CN CNA2006800354264A patent/CN101272781A/zh active Pending
- 2006-07-25 ZA ZA200801825A patent/ZA200801825B/xx unknown
- 2006-07-25 US US11/493,431 patent/US20070082940A1/en not_active Abandoned
- 2006-07-25 WO PCT/US2006/029006 patent/WO2007016155A2/en active Application Filing
- 2006-07-25 JP JP2008524100A patent/JP5184354B2/ja active Active
2008
- 2008-01-24 IL IL189008A patent/IL189008A/en active IP Right Grant
- 2008-02-26 NO NO20081016A patent/NO343037B1/no unknown
- 2008-02-27 KR KR1020087004765A patent/KR101465178B1/ko active IP Right Grant
- 2008-12-12 US US12/334,432 patent/US20090233978A1/en not_active Abandoned
2012
- 2012-02-03 US US13/366,219 patent/US8461196B2/en active Active
- 2012-08-27 JP JP2012186110A patent/JP5767178B2/ja not_active Expired - Fee Related
2013
- 2013-05-05 US US13/887,367 patent/US8877798B2/en active Active
2014
- 2014-09-23 US US14/494,512 patent/US9205074B2/en active Active
2015
- 2015-02-19 JP JP2015030541A patent/JP2015134786A/ja active Pending
- 2015-11-01 US US14/929,361 patent/US9737506B2/en active Active
2016
- 2016-05-05 IL IL245489A patent/IL245489A0/en unknown
2017
- 2017-07-12 US US15/648,424 patent/US10039746B2/en active Active
2018
- 2018-07-05 US US16/028,257 patent/US20190070148A1/en not_active Abandoned
- 2018-10-12 CY CY20181101049T patent/CY1122238T1/el unknown
2020
- 2020-02-28 US US16/805,334 patent/US20210023049A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9737506B2 (en)	2017-08-22
US20090233978A1 (en)	2009-09-17
ZA200801825B (en)	2009-12-30
CA2659215A1 (en)	2007-02-08
KR20140093750A (ko)	2014-07-28
IL189008A (en)	2017-04-30
AU2006275870B2 (en)	2013-01-10
CN104059013A (zh)	2014-09-24
NO343037B1 (no)	2018-10-08
JP5767178B2 (ja)	2015-08-19
KR101465178B1 (ko)	2014-12-02
US20160158197A1 (en)	2016-06-09
IL189008A0 (en)	2008-11-03
CN104059013B (zh)	2016-06-22
JP2009502939A (ja)	2009-01-29
WO2007016155A3 (en)	2007-11-15
CN104059013B8 (zh)	2016-09-21
EP1915146A4 (en)	2010-06-02
BRPI0613943A2 (pt)	2011-02-22
RU2008107336A (ru)	2009-09-10
KR101733180B1 (ko)	2017-05-08
US20130345439A1 (en)	2013-12-26
KR20080042098A (ko)	2008-05-14
JP5184354B2 (ja)	2013-04-17
NO20081016L (no)	2008-04-18
EP2719384A1 (en)	2014-04-16
EP1915146A2 (en)	2008-04-30
US20190070148A1 (en)	2019-03-07
AU2006275870A1 (en)	2007-02-08
JP2013035842A (ja)	2013-02-21
CN101272781A (zh)	2008-09-24
US10039746B2 (en)	2018-08-07
US9205074B2 (en)	2015-12-08
US20070082940A1 (en)	2007-04-12
WO2007016155A2 (en)	2007-02-08
BRPI0613943B1 (pt)	2021-06-22
EP2719384B1 (en)	2018-08-08
KR20170005888A (ko)	2017-01-16
NZ592836A (en)	2013-01-25
US20210023049A1 (en)	2021-01-28
US8877798B2 (en)	2014-11-04
IL245489A0 (en)	2016-06-30
US20180000777A1 (en)	2018-01-04
CY1122238T1 (el)	2020-07-31
US8461196B2 (en)	2013-06-11
JP2015134786A (ja)	2015-07-27
CA2659215C (en)	2018-07-10
US20120302619A1 (en)	2012-11-29
US20150148399A1 (en)	2015-05-28

Publication	Publication Date	Title
IL245489A0 (en)	2016-06-30	New 1-aryl-3-azabicyclo[0.1.3]hexanes, their preparation and their use for the treatment of neuropsychotic disorders
HK1110508A1 (en)	2008-07-18	Compositions and methods of their use for improving the condition and appearance of skin
HK1168104A1 (en)	2012-12-21	Spiro-oxindole compounds and their uses as therapeutic agents
IL186615A0 (en)	2008-01-20	Spiroheterocylic compounds and their uses as therapeutic agents
EP1827407A4 (en)	2008-05-21	METHODS, ASSAYS AND COMPOSITIONS FOR THE TREATMENT OF RETINOL CONDITIONAL DISEASES
IL178402A0 (en)	2007-02-11	1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
ZA200703876B (en)	2008-12-31	2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
EP1888091A4 (en)	2010-06-30	USE OF MAIN OLEOCANTHAL IRRIGATION IN OLIVE OIL AND STRUCTURALLY AND FUNCTIONALLY SIMILAR COMPONENTS
GB2410919B (en)	2009-03-18	Improvements in or relating to the treatment of waste
ZA200903935B (en)	2010-10-27	Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
IL185300A0 (en)	2008-02-09	New pharmaceutical compositions useful in the treatment of parkinson's disease
TWI372047B (en)	2012-09-11	Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
MXPA03008634A (es)	2003-12-08	Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
EP2086328A4 (en)	2011-03-16	NEW ARYLBICYCLO [3.1.0] HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
GB0414594D0 (en)	2004-08-04	Aqueous composition 1
ZA200505989B (en)	2006-12-27	Use the steroids to treat ocular disorders
EP1613318A4 (en)	2009-03-11	COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES
IL190045A0 (en)	2008-12-29	Use of c3-c10 17 alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
PT2719384T (pt)	2018-11-07	Novos 1-naftil-3-azabiciclo[3.1.0]hexanos: preparação e utilização para tratar perturbações neuropsiquiátricas
GB0425633D0 (en)	2004-12-22	Topical formulations for use in the treatment or prevention of dermatological conditions
EP1804795A4 (en)	2007-11-07	ENANTIOMERIC COMPOSITIONS OF CICLETANINE, ALONE OR COMBINED WITH OTHER AGENTS, USED FOR THERAPEUTIC PURPOSES
EP1829860A4 (en)	2011-06-08	9,10-SECOPREGNANDERIVAT AND MEDICINE
EP1660114A4 (en)	2008-06-25	METHOD AND COMPOSITIONS FOR TREATING DYSFUNCTIONS OF THE EXTRACELLULAR MATRIX
GB201001001D0 (en)	2010-03-10	(11C)methoxy-radiolabelled 2,3',4,5'-tetramethylstilbene (TMS) and its preparation and use
GB0418762D0 (en)	2004-09-22	Methods and compositions to treat glaucoma